Chu Chengbiao, Fu Yao, Yang Jun, Fan Xiangshan, Shi Jiong
Department of Pathology, Nanjing Drum Tower Hospital, Nanjing, China.
Front Oncol. 2024 Dec 18;14:1437006. doi: 10.3389/fonc.2024.1437006. eCollection 2024.
Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) is a novel immune checkpoint, similar to programmed death-ligand (PD-L1), and has emerged as a potential target for cancer immunotherapy. Until recently, little was known about the expression and role of Siglec-15 in bladder cancer (BC).
In this study, we used immunohistochemical staining to assess the expression of Siglec-15 and PD-L1 in 69 primary BC samples and analyzed their relationship with clinicopathologic characters and prognosis.
The expression rates of Siglec-15 in the tumor cells, stromal immune cells, and both the tumor and stromal cells were 84.1% (58/69), 50.7% (35/69), and 44.9% (31/69), respectively. The PD-L1 expression rate was 52.2% (36/69), with a positive rate of 17.4% (12/69). PD-L1 expression was inversely correlated with Siglec-15 expression, but the statistical significance was not achieved ( = 0.072). Low stromal Siglec-15 expression was associated with advanced tumor stage ( = 0.010). PD-L1 expression was associated with tumor stage ( = 0.008) and perineural invasion (PNI) ( = 0.048). Kaplan-Meier survival curves showed that stromal Siglec-15 expression was associated with a better prognosis ( = 0.012), although it was not an independent prognostic factor after multivariate analysis ( = 0.236) .
This study revealed a high expression rate of Siglec-15 in BC and may provide valuable insights for patient selection in future clinical trials.
唾液酸结合免疫球蛋白样凝集素15（Siglec-15）是一种新型免疫检查点，类似于程序性死亡配体（PD-L1），已成为癌症免疫治疗的潜在靶点。直到最近，关于Siglec-15在膀胱癌（BC）中的表达和作用仍知之甚少。
在本研究中，我们使用免疫组织化学染色评估了69例原发性BC样本中Siglec-15和PD-L1的表达，并分析了它们与临床病理特征和预后的关系。
Siglec-15在肿瘤细胞、基质免疫细胞以及肿瘤和基质细胞中的表达率分别为84.1%（58/69）、50.7%（35/69）和44.9%（31/69）。PD-L1表达率为52.2%（36/69），阳性率为17.4%（12/69）。PD-L1表达与Siglec-15表达呈负相关，但未达到统计学意义（P = 0.072）。基质Siglec-15低表达与肿瘤晚期相关（P = 0.010）。PD-L1表达与肿瘤分期（P = 0.008）和神经周围浸润（PNI）（P = 0.048）相关。Kaplan-Meier生存曲线显示，基质Siglec-15表达与较好的预后相关（P = 0.012），尽管在多因素分析后它不是独立的预后因素（P = 0.236）。
本研究揭示了Siglec-15在BC中的高表达率，并可能为未来临床试验中的患者选择提供有价值的见解。
